Evidence map›Paper›PMID 25646756›Full record

ArticlePloS one2015

Treatment strategies and survival of older breast cancer patients - an international comparison between the Netherlands and Ireland.

Mandy Kiderlen, Paul M Walsh, Esther Bastiaannet, Maria B Kelly, Riccardo A Audisio, Petra G Boelens, Chris Brown, Olaf M Dekkers, Anton J M de Craen, Cornelis J H van de Velde and 1 more

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Bayesian Generalized Linear Mixed Modeling of Breast Cancer.Iranian journal of public health · 2019
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Mandy KiderlenDept. of Surgery, Leiden University Medical Center, Leiden, The Netherlands; Dept. of Gerontology & Geriatrics, Leiden University Medical Center, Leiden, The Netherlands.
Paul M WalshNational Cancer Registry of Ireland, Cork, Ireland.
Esther BastiaannetDept. of Surgery, Leiden University Medical Center, Leiden, The Netherlands; Dept. of Gerontology & Geriatrics, Leiden University Medical Center, Leiden, The Netherlands.
Maria B KellyNational Cancer Registry of Ireland, Cork, Ireland.
Riccardo A AudisioDepartment of Surgery, St Helens Teaching Hospital, St Helens, United Kingdom; University of Liverpool, Liverpool, United Kingdom.
Petra G BoelensDept. of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Chris BrownNational Cancer Registry of Ireland, Cork, Ireland.
Olaf M DekkersDept. of Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
Anton J M de CraenDept. of Gerontology & Geriatrics, Leiden University Medical Center, Leiden, The Netherlands.
Cornelis J H van de VeldeDept. of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Gerrit-Jan LiefersDept. of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Leiden University Medical Center · NLNational Cancer Registry · IESt Helens Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesForty percent of breast cancers occur among older patients. Unfortunately, there is a lack of evidence for treatment guidelines for older breast cancer patients. The aim of this study is to compare treatment strategy and relative survival for operable breast cancer in the elderly between The Netherlands and Ireland. MATERIAL AND

methodsFrom the Dutch and Irish national cancer registries, women aged ≥65 years with non-metastatic breast cancer were included (2001-2009). Proportions of patients receiving guideline-adherent locoregional treatment, endocrine therapy, and chemotherapy were calculated and compared between the countries by stage. Secondly, 5-year relative survival was calculated by stage and compared between countries.

resultsOverall, 41,055 patients from The Netherlands and 5,826 patients from Ireland were included. Overall, more patients received guideline-adherent locoregional treatment in The Netherlands, overall (80% vs. 68%, adjusted p<0.001), stage I (83% vs. 65%, p<0.001), stage II (80% vs. 74%, p<0.001) and stage III (74% vs. 57%, P<0.001) disease. On the other hand, more systemic treatment was provided in Ireland, where endocrine therapy was prescribed to 92% of hormone receptor-positive patients, compared to 59% in The Netherlands. In The Netherlands, only 6% received chemotherapy, as compared 24% in Ireland. But relative survival was poorer in Ireland (5 years relative survival 89% vs. 83%), especially in stage II (87% vs. 85%) and stage III (61% vs. 58%) patients.

conclusionTreatment for older breast cancer patients differed significantly on all treatment modalities between The Netherlands and Ireland. More locoregional treatment was provided in The Netherlands, and more systemic therapy was provided in Ireland. Relative survival for Irish patients was worse than for their Dutch counterparts. This finding should be a strong recommendation to study breast cancer treatment and survival internationally, with the ultimate goal to equalize the survival rates for breast cancer patients across Europe.

Indexed as

AgedAged, 80 and overAge FactorsBreastBreast NeoplasmsFemaleHumansIrelandNetherlandsRegistriesSurvival Rate

Identifiers

PMID25646756
PMCPMC4315587
OpenAlexW1984133168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.